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Summary
Objective: To identify differentially expressed microRNAs (miRNAs) in human osteoarthritic (OA) cartilage and bone tissue and to determine
their relevance to chondrocyte function.
Methods: Cartilage and bone was obtained from OA patients who underwent total knee joint replacement surgery or from post-mortem pa-
tients with no previous history of OA. MiRNA expression was quantiﬁed by real-time PCR (RT-PCR). Functional pathway analysis of miRNA
was performed using Ingenuity Pathway Analysis. Primary chondrocytes were isolated by collagenase digestion and transfected with miRNA
mimics and miRNA inhibitors using cationic lipid. Tumour Necrosis Factor-alpha (TNF-a) and Matrix metalloprotease 13 (MMP13) protein
levels were measured by Enzyme-Linked ImmunoSorbent Assay (ELISA).
Results: In total we identiﬁed 17 miRNA that showed greater than 4-fold differential expression between OA and normal cartilage, and 30
miRNA that showed greater than 4-fold differential expression in OA bone. Functional pathway analysis of the predicted gene targets for
miR-9, miR-98, which were upregulated in both OA bone and cartilage tissue, and miR-146, which was downregulated in OA cartilage, sug-
gested that these miRNA mediate inﬂammatory functions and pathways. Over-expression of miR-9, miR-98 or miR-146 in isolated human
chondrocytes reduced interleukin-1beta (IL-1b) induced TNF-a production. Furthermore, inhibition and over-expression of miR-9 modulated
MMP13 secretion.
Conclusions: We have identiﬁed a number of differentially expressed miRNAs in late-stage human OA cartilage and bone. Functional analysis
of miR-9, miR-98 and miR-146 in primary chondrocytes suggests a role in mediating the IL-1b induced production of TNF-a. MiR-9, upregu-
lated in OA tissue, was found to inhibit secretion of the collagen type II-targeting metalloproteinase MMP13 in isolated human chondrocytes.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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MicroRNAs (miRNAs) are small non-coding RNA species
that bind to target mRNAs and prevent their translation
into proteins through a process entitled RNA interference1.
Predictive algorithms suggest that up to a third of all human
genes contain putative single or multiple miRNA recognition
elements2. Importantly, the ﬁnding that miRNAs might reg-
ulate multiple genes and the demonstration of differential
expression in animal cells and tissues3,4 has led to specu-
lation that their control of gene expression is conceptually
similar to the action of transcription factors5 although they
act at the translational level.
Greater than 700 miRNAs have so far been identiﬁed and
initial functional studies have demonstrated roles for speciﬁc
miRNA across a range of biological processes including
apoptosis/proliferation6,7, development8e10 and glucose
and lipid metabolism11, whilst differential expression of*Address correspondence and reprint requests to: Simon W.
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464miRNAs have been reported in multiple cancers12,13. Re-
cent work by Kobayshi and colleagues has demonstrated
the importance of miRNA in cartilage function14. They
generated cartilage-speciﬁc Dicer-null mice, Dicer is a crit-
ical enzyme in the miRNA biogenesis pathway. The
growth plates of these mice showed greatly decreased
chondrocyte proliferation and accelerated hypertrophy,
leading to severe growth defects. Hence miRNAs are es-
sential for normal chondrocyte development and function
in the mice. However, at present, little is known about ei-
ther the expression or the functional role of miRNA in os-
teoarthritis (OA). Recently, it was reported that the
cartilage-speciﬁc miRNA140 targets histone deacetylase
4 mRNA15 and the authors proposed a role for miR140
in long bone development. Since inﬂammation is a feature
of OA, with evidence of synovitis in early OA16,17 and the
presence of elevated levels of pro-inﬂammatory cytokines
in synovial ﬂuid, the recent reports that some miRNA me-
diate inﬂammatory pathways are of great interest. Indeed,
it was recently demonstrated that miRNA are rapidly and
transiently upregulated in response to LPS-induced in-
ﬂammation in vitro18,19 and in vivo in the mouse lung20,
whilst expression proﬁling of miRNA in the inﬂammatory
disorders psoriasis and atoptic eczema identiﬁed speciﬁc
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inﬂammed condition21,22. Furthermore, a potential role of
miRNAs in the adaptive immune response has been dem-
onstrated from studies using knockout mice. These stud-
ies showed reduced CD3/CD28-induced IFNg release
from CD4þ T-cells18 and B cell receptor-mediated TNFa
production from B-cells23, indicating that miR-155 facili-
tates or positively regulates cytokine release in lymphoid
cells. Similarly, increased miR-181a expression was also
shown to augment IL-2 release following activation of T-
cells24. Interestingly, recent reports have also shown in-
creased miR-155, miR-146a and miR-146b expression fol-
lowing activation of the innate immune response in
monocytes/macrophages18,19.
In this study we have, for the ﬁrst time, proﬁled the ex-
pression of miRNA in human OA and normal cartilage
and bone. In addition, we have examined the physiological
role of speciﬁc miRNA using both a bioinformatics approach
and through the use of miRNA mimics and inhibitors to
modulate both miRNA expression and activity in primary hu-
man chondrocytes to determine their effect on speciﬁc cat-
abolic pathways.
Materials and methodsPREPARATION OF HUMAN CARTILAGE AND BONE FROM
DONOR KNEESHuman OA cartilage and bone was obtained following total knee replace-
ment operations (age range of between 66 and 71 years), whilst normal car-
tilage and bone was taken from post-mortem donors (age range of between
63 and 70 years) with no previous history of joint pain (n¼ 3 cartilage; n¼ 4
bone). Full ethical consent was obtained from all donors and families.ISOLATION OF PRIMARY HUMAN CHONDROCYTESTo isolate primary chondrocytes, slices of cartilage were stripped from the
femoral condyles and tibial plateaux, cut into small pieces using a scalpel
blade and digested in growth media (DMEM supplemented with 10% FCS,
penicillin (100 units/ml), streptomycin (100 mg/ml), 2 mM L-glutamine, non-es-
sential amino acids (Invitrogen) and amphotericin (2.5 mg/ml)) containing 1%
collagenase type IA (0.5e3.0 FALGPA units/mg, Sigma, Dorset, UK). Fol-
lowing overnight incubation at 37C, the sample was ﬁltered to remove un-
digested cartilage and chondrocyte cells pelleted at 2000 g for 5 min
before being resuspended in growth media and grown in monolayer.MiRNA ISOLATION AND QUANTIFICATIONCartilage and bone tissue (0.5 g) from the knees of OA and normal donors
was crushed to a powder using a Freezer Mill (Glen Creston, London, UK.)
and total RNA (including the microRNA fraction) extracted by homogenisa-
tion using a polytron in 6 vol of Trizol reagent (Invitrogen, UK). Total RNA
was also extracted from primary human chondrocytes by adding Trizol re-
agent directly to the chondrocyte cells grown on tissue culture plates. RNA
was resuspended in 50 ml RNase-free water (Promega UK, Southampton,
UK) and quantiﬁed by using a spectrophotometer (Nanodrop) and using an
Agilent Bioanalyser to conﬁrm quality. MiRNA expression proﬁling was car-
ried out on total RNA extracts by two-step Taqman RT-PCR, normalised
to 18S. Reverse transcription was carried out on 5 ng of total RNA in
7.5 ml reactions using the TaqMan MicroRNA Reverse Transcription Kit us-
ing RT stem-loop primers (Applied Biosystems, Warrington, UK) according to
the manufacturer’s instructions. The expression proﬁle of 157 human miRNA
was then determined using the Human Panel Early Access kit (Applied Bio-
systems) according to the manufacturer’s instructions. The reaction was car-
ried out using a 7700 Real Time PCR system (Applied Biosystems) in 10 ml
reaction volumes. In a separate reaction, 1-step PCR (Qiagen) was per-
formed on the total RNA for 18S quantiﬁcation, which was used as the en-
dogenous control for data normalisation.FUNCTIONAL PATHWAY ANALYSIS OF SPECIFIC miRNAsComputationally predicted gene targets for miR-9, miR-98 and miR-146
were obtained from the MicroCosm web resource (Sanger) using the mi-
Randa algorithm. Selecting the top 200 target sequences based on the con-
ﬁdence of the hit we uploaded these gene targets into the Ingenuity PathwayAnalysis application (Ingenuity Systems, www.ingenuity.com) to generate
a network of candidate miRNA gene targets. Functional analysis of the net-
work was then performed to identify the biological functions and/or diseases
that were most signiﬁcant to the genes in the network. Fisher’s exact test
was used to calculate the probability that each biological function and/or dis-
ease assigned to that network was due to chance alone. Canonical path-
ways analysis was performed to identify pathways from the Ingenuity
Pathway Analysis library of canonical pathways that were most signiﬁcant
to the genes in the network. The signiﬁcance of the association of a given
canonical pathway and the network of gene targets was measured in two
ways. Firstly, by the ratio of the number of genes in the network that mapped
to the canonical pathway divided by the total number of genes that map to
the canonical pathway. Secondly, Fisher’s exact test was used to calculate
a P-value of the association between the genes in the network and the ca-
nonical pathway.MiRNA MODULATION USING miRNA MIMICS AND INHIBITORSHuman primary OA chondrocytes were transfected with pre-miRNA
mimics (Applied Biosystems) or with Locked Nucleic Acid (LNA) miRNA in-
hibitors (Exiqon) using cationic Atufect lipid (Atugen) for 24 h. Following
transfection cells were stimulated with IL-1b for 24 h and the cell superna-
tants harvested for subsequent protein analysis by ELISA.ANALYSIS OF THE PRODUCTION OF TNFa AND
MMP13 PROTEINConditioned media from transfected cells was assayed for levels of
TNF-a using a commercially available ELISA kit (R&D systems). In brief,
polystyrene high-binding plates (Costar) were coated overnight at 4C with
capture antibody diluted 1:500 to 4 mg/ml. After removal of the coating anti-
body, plates were blocked in Phosphate Buffered Saline (PBS) containing
1% BSA before addition of 40 ml of either sample or standard together with
the detection antibody 20 ml/well diluted 1:1000. Plates were then left a further
2 h at room temperature before the addition of Streptavidin HRP. MMP13
protein levels were determined using an in-house ELISA utilising a polyclonal
MMP13 antibody (Abcam; ab9128), diluted 1:2500 in PBS and a secondary
anti-rabbit HRP conjugate (GE Healthcare; NA934). All plates were devel-
oped with the addition of 40 ml/well of TMB for 20 min in the dark at room tem-
perature, and reactions stopped with the addition of H2SO4 (2M) before the
absorbance read on a plate reader (Pherostar).STATISTICAL ANALYSISAll data are reported as means S.E.M. Comparisons were performed us-
ing Analysis of variance (ANOVA) and post-hoc tests used to test for signif-
icance, with signiﬁcance accepted as P< 0.05.ResultsMiRNA ARE DIFFERENTIALLY EXPRESSED IN OA BONE
AND CARTILAGEIn order to obtain sufﬁcient quantity of miRNA for subse-
quent quantiﬁcation analysis it was necessary to extract to-
tal RNA from cartilage and bone tissue using Trizol reagent.
A comparison of the Bioanalyser gel proﬁle from the total
RNA extraction with the gel proﬁle of isolated miRNA using
the mirVana kit shows that total RNA extractions using Tri-
zol retain the miRNA fraction (Fig. 1).
Expression proﬁling of 157 human miRNA extracted from
OA and normal cartilage (n¼ 3) identiﬁed 17 miRNA which
showed differential expression of greater than 4-fold between
diseased and normal tissue (Table I). Among themost notable
changes were miR-9, miR-25 and miR-98, which were upre-
gulated by 8-, 8- and 23-fold respectively (P< 0.05), miR-
146, which was downregulated by 14-fold (P< 0.05) and
miR-149 that was downregulated 27 fold (P< 0.01, Table I).
For reference, we also examined the miRNA proﬁle of OA
and normal bone. We found that 30 miRNA were identiﬁed
with differential expression of greater than 4-fold between
diseased and normal bone tissue (Table I). Of these the
miRNA showing the greatest fold change were miR27a,
miR34b and miR-98, which were upregulated in OA bone
Fig. 1. Isolation of miRNA fraction in human OA tissue. A comparison of BioAnalyser gel proﬁles for total RNA extraction using Trizol and
miRNA extraction when isolated using the mirVana kit. MiRNA fraction can be seen in the total RNA prep.
Table 1
MiRNA with 4-fold differential expression between OA and normal
tissue. Positive fold change values indicate elevated expression in
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was downregulated by 4-fold in OA bone (P< 0.05). Of par-
ticular interest was the ﬁnding that miR-9 and miR-98, which
we had previously identiﬁed as being upregulated in OA car-
tilage, were also upregulated in OA bone (Table I).OA tissue, whilst negative fold change values indicate elevated ex-
pression in normal tissue. *¼ significantly different from normal
control value
DIFFERENTIALLY EXPRESSED miRNA MAY MEDIATE
INFLAMMATORY PATHWAYSmiRNA Cartilage miRNA Bone
Fold Change P Value Fold Change P Value
miR-9 8 0.04* miR-9 4 0.03*
miR-25 8 0.03* miR-19a 4 0.18
miR-34a 4 0.49 miR-21 19 0.06
miR-34b 8 0.29 miR-23a 4 0.17
miR-98 23 0.02* miR-27a 33 0.08
miR-107 4 0.01* miR-27b 5 0.09
miR-130b 7 0.36 miR-31 21 0.07
miR-137 5 0.54 miR-34b >100 0.04*
miR-146 14 0.04* miR-34c 21 0.1
miR-148 5 0.28 miR-98 >100 0.02*
miR-149 27 <0.01* miR-100 7 0.14
miR-182 4 0.48 miR-104 23 0.04*
miR-185 4 0.12 miR-105 4 0.02*
miR-200a 11 <0.01* miR-122a 9 0.04*
miR-211 5 <0.01* miR-135a 4 0.02*
miR-299 5 0.02* miR-135b 5 0.01*
miR-342 4 0.06 miR-139 6 <0.01*
miR-142-3 5 0.06
miR-144 5 0.04*
miR-147 8 0.01*
miR-148 20 0.04*
miR-149 11 0.03*
miR-181a 4 0.15
miR-187 8 0.11
miR-210 5 0.053
miR-299 5 0.11
miR-302d 22 0.04*
miR-330 4 0.08
miR-335 12 0.08
miR-340 9 0.36In determining the functional role of differentially ex-
pressed miRNA in OA we focussed on miR-9, miR-98 and
miR-146. MiR-9 and miR-98 were selected as highly upre-
gulated miRNA species and because they were also
strongly upregulated in OA bone tissue. MiR-146 was se-
lected because it was highly downregulated in OA cartilage
and the evidence from literature that miR-146 may play
a role in inﬂammation18,19.
In order to explore the functional relevance of the se-
lected miRNA species in human chondrocytes we under-
took a bioinformatics analysis approach to guide
experimental design. The principle aim of this work was
not to identify speciﬁc miRNA gene targets and establish
mechanistic linkages but rather to determine the functional
relevance of miRNA on OA-relevant chondrocyte pheno-
types. Firstly, we performed functional pathway analysis
of the top 200 (based on conﬁdence hit) predicted mRNA
gene targets of miR-9, miR-98 and miR-146 using the Inge-
nuity Pathway Analysis application to identify signiﬁcant
biological functions and canonical pathways. Core func-
tional analysis revealed that for both miR-9 and miR-98
(which were upregulated in OA bone and OA cartilage)
one of the most signiﬁcant biological functions was inﬂam-
matory disease, with a total of 38 and 32 gene targets of
miR-9 and miR-98 respectively linked to inﬂammation and
inﬂammatory disorders, including arthritis [Figs. 2(a) and
3(a)]. Of these putative gene targets 7 were common to
both miR-9 and miR-98 namely alpha-1-microglobulin/biku-
nin precursor (AMBP), Bux non-receptor tyrosine kinase
(BMX), apolipoprotein E (APOE), major histocompatability
Fig. 2. Pathway analysis of miR-9. Core functional pathway analysis using Ingenuity Pathway Analysis application of the top 200 predicted
gene targets of miR-9. (a) Most signiﬁcant biological functions mapped to the network of miR-9 gene targets. Threshold bar shows cut-off point
of signiﬁcance P< 0.05, log(P-value) of 1.3. (b) Most signiﬁcant canonical signalling pathways from the Ingenuity canonical pathway library
mapped to the network of miR-9 gene targets. Threshold bar shows cut-off point of signiﬁcance P< 0.05, log(P-value) of 1.3. Line shows
ratio of genes in network to total number of genes in canonical pathway. (c) Network of miR-9 gene targets linked to biological functions
inﬂammation, rheumatoid arthritis and arthritis.
467Osteoarthritis and Cartilage Vol. 17, No. 4
Fig. 3. Pathway analysis of miR-98. Core functional pathway analysis using Ingenuity Pathway Analysis application of the top 200 predicted
gene targets of miR-98. (a) Most signiﬁcant biological functions mapped to the network of miR-98 gene targets. Threshold bar shows cut-off
point of signiﬁcance P< 0.05, log(P-value) of 1.3. (b) Most signiﬁcant canonical signalling pathways from the Ingenuity canonical pathway
library mapped to the network of miR-98 gene targets. Threshold bar shows cut-off point of signiﬁcance P< 0.05, log(P-value) of 1.3. Line
shows ratio of genes in network to total number of genes in canonical pathway. (c) Network of miR-98 gene targets linked to biological func-
tions inﬂammation, rheumatoid arthritis and arthritis.
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469Osteoarthritis and Cartilage Vol. 17, No. 4complex Class I, B (HLA-B), Runt-related transcription factor
3 (RUNX3), complement component 1, subcomponent
(C1R) and amphiregulin (AREG) [Figs. 2(c) and 3(c)].
Canonical pathway analysis was then used to identify
pathways from the Ingenuity Pathway Analysis library
that were most signiﬁcant to the predicted miRNA gene tar-
gets. Canonical pathway analysis of the miR-9 gene targets
found that the three most signiﬁcant pathways were PXR/
RXR activation, G-protein coupled receptor (GPCR) signal-
ling and Wnt/b-catenin signalling, whilst for miR-98 the most
signiﬁcant pathways were apoptosis signalling, leukocyte
extravasation signalling and complement system. Strikingly,
canonical pathway analysis of the top 200 predicted gene
targets of miR-146 mapped only one pathway that was
clearly signiﬁcant, which was the NFkB signalling pathway
with a total of 9 genes potentially targeted by miR-146 pres-
ent in the pathway [Fig. 4(b), (c)]. As stated above, this bio-
informatics approach utilises predicted genes targets based
on the miRANDA alogithim and therefore a degree of cau-
tion should be taken in interpreting these ﬁndings. However,
the mapping of miR-9, miR-98 and miR-146 gene targets to
inﬂammatory pathways (including the NFkB signalling path-
way) suggested that determining the effect of modulating
these microRNA on TNF-a and MMP13 production would
be of signiﬁcant interest given the these functionally OA rel-
evant end-points are known to be mediated by inﬂammatory
pathways25.DIFFERENTIALLY EXPRESSED miRNA MEDIATE THE
SECRETION OF TNF-a AND MMP13 PROTEIN IN
HUMAN PRIMARY CHONDROCYTESIn order to further study the functional role of miR-9, miR-
98 and miR-146 we modulated both the expression and ac-
tivity of these miRNA in chondrocytes and examined the ef-
fect on two functional biological assays representative of
inﬂammation pathways: TNF-a and a gene target regulated
by TNF-a of particular relevance to OA disease, namely
matrix metalloproteinase-13 (MMP13). IL-1b is an activator
of NFkB and a cytokine associated with OA; thus, the ef-
fects of miRNA modulation on TNF-a and MMP-13 protein
production were explored both at a basal level and following
induction with IL-1b.
Using LNA inhibitors of miR-9, miR-98 and miR-146,
basal TNF-a protein was marginally elevated by between
21 and 48% at the highest concentration relative to a control
LNA miRNA inhibitor (Fig. 5a). Consistent with this, over-ex-
pression of the each of the miRNA species, had no effect on
basal TNF-a levels. However, over-expression of miRNAs
signiﬁcantly attenuated IL-1b inducted TNF-a by 40%,
62% and 56% (P< 0.05) for miR-9, miR-98 and miR-146 re-
spectively [Fig. 5(b)].
We next examined the effect of miRNA modulation on the
secretion of MMP13 protein by chondrocytes and found that
upon inhibition of miR-9 by speciﬁc LNA there was a trend
to an elevation of basalMMP13protein levels anda signiﬁcant
increase (P< 0.05) in the IL-1b induction of MMP13 protein
[Fig. 6(a)]. Conversely, when miR-9 was over-expressed
both basal and IL-1b-induced MMP13 levels were reduced
[Fig. 6(b)]. Inhibition and over-expression of miR-98 and
miR-146 did not appear to have any effect on either basal or
IL-1b-induced MMP13 levels [Fig. 6(a) and (b)] respectively.
Discussion
In attempting to understand the biological pathways and
processes that underlie the pathogenesis and progressionof osteoarthritic disease genomic approaches have identi-
ﬁed genes associated with the extraceullular matrix, oxida-
tive stress, phenotype stabilisation and IL-1 signalling as
being differentially expressed in OA disease26e28. Our un-
derstanding of how these key pathways are regulated and
how they become dysregulated in disease is critical in at-
tempting to develop novel therapeutic entities. In this con-
text, the identiﬁcation of endogenously expressed miRNA
species that regulate the post-transcriptional expression of
multiple genes and possibly therefore whole biological path-
ways and processes is of great interest.
In this study we have proﬁled the expression of 157 human
miRNA and identiﬁed a number of miRNAs that are differen-
tially expressed in human OA cartilage and OA bone com-
pared to non-diseased tissue. Focussing on miR-9 and
miR-98 (which were upregulated in both OA cartilage and
OA bone tissue), and miR-146 (which was downregulated
in OA cartilage) we have performed a bioinformatics
approach, which indicated that miR-9 and miR-98 have the
potential to target a signiﬁcant number of genes involved in
inﬂammatory diseases, whilst miR-146 was associated with
a signiﬁcant number of genes within the NFkB pathway.
We found that miR-9 was upregulated in OA cartilage,
and furthermore that over-expression in isolated chondro-
cytes decreased MMP13 secretion, while inhibition of
miR-9 increased levels of this metalloproteinase. In line
with this, MMP13 has been shown to be downregulated in
late-stage human OA cartilage29.
The ﬁnding that over-expression of miR-9, miR-98 and
miR-146 reduced the IL-1b mediated production of TNF-
a and that over-expression of miR-9 reduced basal and
IL-1b induced MMP13 protein release suggests that these
miRNA may play a protective role in OA disease. Therefore,
the observation that miR-9 and miR-98 are both upregu-
lated in OA cartilage and OA bone tissue might suggest
that their expression is triggered as part of a negative-feed-
back mechanism or in response to activated pro-inﬂamma-
tory pathways. Neither miR-9 nor miR-98 have previously
been implicated in mediating inﬂammatory processes.
AREG was predicted to be targeted by both these miRNAs,
which as stated above were both upregulated in OA tissue.
Interestingly, AREG has recently been proposed as a pro-
inﬂammatory mediator in the pathogenesis of rheumatoid
arthritis (RA), with elevated levels detected in the synovial
ﬂuid in RA compared to OA patients30 Hence miR-9 and
miR-98 may be inhibiting AREG function in the context of
OA, but at present this is speculative, since direct binding
of these miRNAs to AREG needs to be assessed.
Recent studies have suggested a role for miR-9 in neuro-
nal development of the spinal cord31, neuronal dysfunction
in Alzheimer’s disease32 and insulin release from pancre-
atic cells33, whilst miR-98 expression has been associated
with head and neck cancers34.
One of the most interesting ﬁndings of the pathway anal-
ysis was the signiﬁcant proportion of miR-146 predicted
gene targets that mapped to the NFkB pathway, suggesting
miR-146 plays a role in mediating NFkB signalling. Al-
though further work is required to fully validate the role of
mir-146 in NFkB signalling it is of interest that two predicted
gene targets of miR-146, namely IRAK1 and TRAF6, are
key adaptor molecules in toll-like receptor and IL-1 receptor
signalling cascades that are thought mediate activation of
NFkB and AP-1 pathways. Indeed both IRAK1 and
TRAF6 have now been shown experimentally to be direct
targets of miR-14619, which strengthens the suggestion
from our bioinformatics analysis that miR-146 is involved
in the NFkB signalling pathway.
Fig. 4. Pathway analysis of miR-146. Core functional pathway analysis using Ingenuity Pathway Analysis application of the top 200 predicted
gene targets of miR-146. (a) Most signiﬁcant biological functions mapped to the network of miR-146 gene targets. Threshold bar shows cut-off
point of signiﬁcance P< 0.05, log(P-value) of 1.3 using Fisher’s exact test. (b) Most signiﬁcant canonical signalling pathways from the In-
genuity canonical pathway library mapped to the network of miR-146 gene targets. Threshold bar shows cut-off point of signiﬁcance P< 0.05,
log(P-value) of 1.3 using Fisher’s exact test. Line shows ratio of genes in network to total number of genes in canonical pathway. (c) Network
of miR-146 gene targets linked to the NFkB signalling pathway.
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Fig. 5. MiR-9, miR-98 and miR-146 decrease IL-1 induced TNF-a secretion by human chondrocytes (a) The effect of inhibition of miR-9, miR-
98 and miR-146 using LNA inhibitors on basal TNF-a protein production in human primary OA chondrocytes. Bars show mean % TNF-a pro-
tein S.E.M. (n¼ 3) relative to media control. (b) The effect of over-expression of miR-9, miR-98 and miR-146 on the basal and IL-1b-induced
TNF-a protein. Bars represent mean % TNF-a protein S.E.M. (n¼ 3) relative to media control. *¼P< 0.05, signiﬁcantly different from corre-
sponding control value.
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ated elevation of miR-146 in THP1 cells occurs in an NFkB
dependent manner19, which opens up the possibility that
miR-146 is induced as a negative feedback regulator of in-
ﬂammation. MiR-146 has recently been detected at higher
levels in the synovium from rheumatoid arthritis patients
compared to OA patients35. Our ﬁndings show that miR-
146 is downregulated in late-stage OA cartilage, whileFig. 6. MiR-9, but not miR-98 nor miR-146 decreases MMP13 secretion b
and miR-146 using LNA inhibitors on basal and IL-1b-induced MMP13 p
mean % MMP13 protein S.E.M. (n¼3). *¼P< 0.05, signiﬁcantly differen
over-expression of miR-9, miR-98 and miR-146 on basal and IL-1b-induc
sent mean % MMP13 protein S.E.M. (n¼ 3). *¼P< 0.05, sover-expression negatively effects TNF-a levels suggest
that reduced miR-146 expression in OA cartilage could be
a factor in the promotion of an inﬂammatory OA state, at least
in the latter stages of the disease. Mir-146 is not predicted to
directly target TNF-a and indeed over-expression ofmiR-146
did not affect basal TNF-a secretion from chondrocytes.
However, the fact that IL-1b-induced production of TNF-
a was signiﬁcantly reduced by miR-146 over-expressiony human chondrocytes (a) The effect of inhibition of miR-9, miR-98
rotein production in human primary OA chondrocytes. Bars show
t from corresponding LNA control inhibitor value. (b) The effect of
ed MMP13 protein in primary human OA chondrocytes. Bars repre-
igniﬁcantly different from corresponding control value.
472 S. W. Jones et al.: The identiﬁcation of differentially expressed microRNA in osteoarthritic tissuecould conceivably be due to direct targeting of IL-1 receptor-
associated kinase 1 (IRAK1) - a known miR-146 target19.
Current approaches to developing disease-modifying
drugs in OA have focussed on inhibition of the MMPs (e.g
MMP13) or modulating IL-1b either directly or via signal
transduction (e.g prostaglandin J2). Understanding the reg-
ulation of miRNAs or directly targeting groups of key miRNA
identiﬁed as playing a role in the disease process may be
a valid alternative therapeutic approach. Indeed, a small
number of miRNA therapies are being explored in cancer,
viral infection, metabolic disorders and inﬂammatory dis-
ease. In considering whether particular miRNA have value
either as therapeutics it is important to consider their spe-
cies conservation in order that in vivo efﬁcacy against bio-
markers of disease can be demonstrated. Analysis of
miR-146 transcripts using the Sanger registry shows that
miR-146 is evolutionary well conserved, with close homol-
ogy between rodent (for which there are established OA
models) and human miR-146.
In summary, given the role of miRNA in mediating the
translation of target mRNA into protein, the identiﬁcation
of differentially expressed miRNA in OA tissue we report
here could have important diagnostic and therapeutic
potential. The ability to selectively control aberrant pro-
tein expression through miRNA could provide a novel
means to treat OA disease, whilst the differentially ex-
pressed miRNAs we have identiﬁed could prove to be
useful diagnostic ‘‘at-risk’’ biomarkers of OA disease
progression.
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